Immunologic Research

, Volume 47, Issue 1–3, pp 25–44 | Cite as

Mechanisms involved in antibody- and complement-mediated allograft rejection

Article

Abstract

Antibody-mediated rejection has become critical clinically because this form of rejection is usually unresponsive to conventional anti-rejection therapy, and therefore, it has been recognized as a major cause of allograft loss. Our group developed experimental animal models of vascularized organ transplantation to study pathogenesis of antibody- and complement-mediated endothelial cell injury leading to graft rejection. In this review, we discuss mechanisms of antibody-mediated graft rejection resulting from activation of complement by C1q- and MBL (mannose-binding lectin)-dependent pathways and interactions with a variety of effector cells, including macrophages and monocytes through Fcγ receptors and complement receptors.

Keywords

Alloantibody Complement Ig knockout mice Cardiac rejection vWf C4d MBL Fcγ and complement receptors Endothelial cells Macrophages 

References

  1. 1.
    Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969;280:735–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Feucht HE, Felber E, Gokel MJ, Hillebrand G, Nattermann U, Brockmeyer C, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol. 1991;86:464–70.PubMedGoogle Scholar
  3. 3.
    Lederer SR, Schneeberger H, Albert E, Johnson JP, Gruber R, Land W, et al. Early renal graft dysfunction. The role of preformed antibodies to DR-typed lymphoblastoid cell lines. Transplantation. 1996;61:213–9.Google Scholar
  4. 4.
    Baldwin WM III, Pruitt SK, Brauer RB, Daha MR, Sanfilippo F. Complement in organ transplantation: contribution to inflammation, injury and rejection. Transplantation. 1995;59:797–808.PubMedGoogle Scholar
  5. 5.
    Smith RN, Brousaides N, Grazette L, Saidman S, Semigran M, Disalvo T, et al. C4d deposition in cardiac allografts correlates with alloantibody. J Heart Lung Transpl. 2005;24:1202–10.Google Scholar
  6. 6.
    Smith RN, Kawai T, Boskovic S, Nadazdin O, Sachs DH, Cosimi AB, et al. Chronic antibody mediated rejection of renal allografts: pathological, serological and immunologic features in nonhuman primates. Am J Transpl. 2006;6:1790–8.Google Scholar
  7. 7.
    Uehara S, Chase CM, Cornell LD, Madsen JC, Russell PS, Colvin RB. Chronic cardiac transplant arteriopathy in mice: relationship of alloantibody, C4d deposition and neointimal fibrosis. Am J Transpl. 2007;7:57–65.Google Scholar
  8. 8.
    Wehner J, Morrell CN, Reynolds T, Rodriguez ER, Baldwin WM 3rd. Antibody and complement in transplant vasculopathy. Circ Res. 2007;100:191–203.PubMedGoogle Scholar
  9. 9.
    Jordan S. IVIG vs. plasmapheresis for desensitization: which is better? Am J Transpl. 2006;6:1510–1.Google Scholar
  10. 10.
    Jordan SC, Vo AA, Peng A, Toyoda M, Tyan D. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transpl. 2006;6:459–66.Google Scholar
  11. 11.
    Montgomery RA, Cooper M, Kraus E, Rabb H, Samaniego M, Simpkins CE et al. Renal transplantation at the Johns Hopkins Comprehensive Transplant Center. Clin Transpl. 2003:199–213.Google Scholar
  12. 12.
    Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center’s perspective. Pediatr Transpl. 2004;8:535–42.Google Scholar
  13. 13.
    Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick JF, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation. 2000;70:887–95.PubMedGoogle Scholar
  14. 14.
    Haas M, Montgomery RA, Segev DL, Rahman MH, Racusen LC, Bagnasco SM, et al. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transpl. 2007;7:576–85.Google Scholar
  15. 15.
    Warren DS, Zachary AA, Sonnenday CJ, King KE, Cooper M, Ratner LE, et al. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transpl. 2004;4:561–8.Google Scholar
  16. 16.
    Haas M, Rahman MH, Racusen LC, Kraus ES, Bagnasco SM, Segev DL, et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. Am J Transpl. 2006;6:1829–40.Google Scholar
  17. 17.
    Tang AH, Platt JL. Accommodation of grafts: implications for health and disease. Hum Immunol. 2007;68:645–51.PubMedGoogle Scholar
  18. 18.
    Platt JL. C4d and the fate of organ allografts. J Am Soc Nephrol. 2002;13:2417–9.PubMedGoogle Scholar
  19. 19.
    Lynch RJ, Platt JL. Accommodation in organ transplantation. Curr Opin Organ Transpl. 2008;13:165–70.Google Scholar
  20. 20.
    Feucht HE, Opelz G. The humoral immune response towards HLA class II determinants in renal transplantation. Kidney Int. 1996;50:1464–75.PubMedGoogle Scholar
  21. 21.
    Collins AB, Schneeberger EE, Pascual MA, Saidman SL, Williams WW, Tolkoff N, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol. 1999;10:2208–14.PubMedGoogle Scholar
  22. 22.
    Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, et al. Antibody-mediated rejection criteria—an addition to the banff 97 classification of renal allograft rejection. Am J Transpl. 2003;3:708–14.Google Scholar
  23. 23.
    Feucht HE. Complement C4d in graft capillaries—the missing link in the recognition of humoral alloreactivity. Am J Transpl. 2003;3:646–52.Google Scholar
  24. 24.
    Mauiyyedi S, Colvin RB. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens. 2002;11:609–18.PubMedGoogle Scholar
  25. 25.
    Herzenberg AM, Gill JS, Djurdjev O, Magil AB. C4d deposition in acute rejection: an independent long-term prognostic factor. J Am Soc Nephrol. 2002;13:234–41.PubMedGoogle Scholar
  26. 26.
    Lederer SR, Kluth-Pepper B, Schneeberger H, Albert E, Land W, Feucht HE. Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int. 2001;59:334–41.PubMedGoogle Scholar
  27. 27.
    Michaels PJ, Espejo ML, Kobashigawa J, Alejos JC, Burch C, Takemoto S, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transpl. 2003;22:58–69.Google Scholar
  28. 28.
    Mengel M, Bogers J, Bosmans JL, Seron D, Moreso F, Carrera M, et al. Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial. Am J Transpl. 2005;5:1050–6.Google Scholar
  29. 29.
    Rodriguez ER, Skojec DV, Tan CD, Zachary AA, Kasper EK, Conte JV, et al. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transpl. 2005;5:2778–85.Google Scholar
  30. 30.
    Baldwin WM III, Flavahan NA, Fairchild RL. Integration of complement and leukocytes in response to allotransplantation. Curr Opin Transpl. 2002;7:92–9.Google Scholar
  31. 31.
    Baldwin WM III, Larsen CP, Fairchild RL. Innate immune responses to transplants: a significant variable with cadaver donors. Immunity. 2001;14:369–76.PubMedGoogle Scholar
  32. 32.
    Sacks SH, Chowdhury P, Zhou W. Role of the complement system in rejection. Curr Opin Immunol. 2003;15:487–92.PubMedGoogle Scholar
  33. 33.
    Sacks SH, Zhou W. Locally produced complement and its role in renal allograft rejection. Am J Transpl. 2003;3:927–32.Google Scholar
  34. 34.
    Qian Z, Wasowska BA, Behrens E, Brody JR, Kadkol SS, Cangello DL, et al. C6 produced by macrophages contributes to cardiac allograft rejection. Am J Pathol. 1999;155:1293–302.PubMedGoogle Scholar
  35. 35.
    Nakashima S, Qian Z, Rahimi S, Wasowska BA, Baldwin WM 3rd. Membrane attack complex contributes to destruction of vascular integrity in acute lung allograft rejection. J Immunol. 2002;169:4620–7.PubMedGoogle Scholar
  36. 36.
    Nakashima S, Soong TR, Fox-Talbot K, Qian Z, Rahimi S, Wasowska BA, et al. Impact of MHC class II incompatibility on localization of mononuclear cell infiltrates to the bronchiolar compartment of orthotopic lung allografts. Am J Transpl. 2005;5:694–701.Google Scholar
  37. 37.
    Marsh JE, Farmer CK, Jurcevic S, Wang Y, Carroll MC, Sacks SH. The allogeneic T and B cell response is strongly dependent on complement components C3 and C4. Transplantation. 2001;72:1310–8.PubMedGoogle Scholar
  38. 38.
    Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med. 2002;8:582–7.PubMedGoogle Scholar
  39. 39.
    Li K, Patel H, Farrar CA, Hargreaves RE, Sacks SH, Zhou W. Complement regulates the capacity of proximal tubular epithelial cell to stimulate alloreactive T cell response. J Am Soc Nephrol. 2004;15:2414–22.PubMedGoogle Scholar
  40. 40.
    Wasowska BA, Qian Z, Cangello DL, Behrens E, Van Tran K, Layton J, et al. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice. Transplantation. 2001;71:727–36.PubMedGoogle Scholar
  41. 41.
    Rahimi S, Qian Z, Layton J, Fox-Talbot K, Baldwin WM, Wasowska BA. Non-complement and complement activating antibodies synergize to cause rejection of cardiac allografts. Am J Transpl. 2004;4:326–34.Google Scholar
  42. 42.
    Murata K, Fox-Talbot K, Qian Z, Takahashi K, Stahl GL, Baldwin WM, Wasowska BA. Synergistic deposition of C4d by complement-activating and non-activating antibodies in cardiac transplants. Am J Transpl. 2007;7:2605–14.Google Scholar
  43. 43.
    Brandle D, Joergensen J, Zenke G, Burki K, Hof RP. Contribution of donor-specific antibodies to acute allograft rejection: evidence from B cell-deficient mice. Transplantation. 1998;65:1489–93.PubMedGoogle Scholar
  44. 44.
    Jindra PT, Hsueh A, Hong L, Gjertson D, Shen XD, Gao F, et al. Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J Immunol. 2008;180:2214–24.PubMedGoogle Scholar
  45. 45.
    Wasowska BA, Qian Z, Behrens E, Cangello D, Sanfilippo F, Baldwin WM III. Inhibition of acute cardiac allograft rejection in immunoglobulin-deficient mice. Transpl Proc. 1999;31:136.Google Scholar
  46. 46.
    Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 2001;19:225–52.PubMedGoogle Scholar
  47. 47.
    Reed EF, Demetris AJ, Hammond E, Itescu S, Kobashigawa JA, Reinsmoen NL, et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transpl. 2006;25:153–9.Google Scholar
  48. 48.
    Meehan SM, Limsrichamrern S, Manaligod JR, Junsanto T, Josephson MA, Thistlethwaite JR. Platelets and capillary injury in acute humoral rejection of renal allografts. Hum Pathol. 2003;34:533–40.PubMedGoogle Scholar
  49. 49.
    Morrell CN, Murata K, Swaim AM, Mason E, Martin TV, Thompson LE, et al. In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody. Circ Res. 2008;102:777–85.PubMedGoogle Scholar
  50. 50.
    Ota H, Fox-Talbot K, Hu W, Qian Z, Sanfilippo F, Hruban RH, et al. Terminal complement components mediate release of von Willebrand factor and adhesion of platelets in arteries of allografts. Transplantation. 2005;79:276–81.PubMedGoogle Scholar
  51. 51.
    Morrell CN, Sun H, Swaim AM, Baldwin WM 3rd. Platelets an inflammatory force in transplantation. Am J Transpl. 2007;7:2447–54.Google Scholar
  52. 52.
    Kirk AD, Morrell CN, Baldwin WM 3rd. Platelets influence vascularized organ transplants from start to finish. Am J Transpl. 2009;9:14–22.Google Scholar
  53. 53.
    Saadi S, Holzknecht RA, Patte CP, Platt JL. Endothelial cell activation by pore-forming structures: pivotal role for interleukin-1alpha. Circulation. 2000;101:1867–73.PubMedGoogle Scholar
  54. 54.
    Saadi S, Holzknecht RA, Patte CP, Stern DM, Platt JL. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med. 1995;182:1807–14.PubMedGoogle Scholar
  55. 55.
    Tedesco F, Pausa M, Nardon E, Introna M, Mantovani A, Dobrina A. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med. 1997;185:1619–27.PubMedGoogle Scholar
  56. 56.
    Schulte am Esch J II, Cruz MA, Siegel JB, Anrather J, Robson SC. Activation of human platelets by the membrane-expressed A1 domain of von Willebrand factor. Blood. 1997;90:4425–37.PubMedGoogle Scholar
  57. 57.
    Bombeli T, Schwartz BR, Harlan JM. Adhesion of activated platelets to endothelial cells: evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), alphavbeta3 integrin, and GPIbalpha. J Exp Med. 1998;187:329–39.PubMedGoogle Scholar
  58. 58.
    Yamakuchi M, Kirkiles-Smith NC, Ferlito M, Cameron SJ, Bao C, Fox-Talbot K, et al. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci USA. 2007;104:1301–6.PubMedGoogle Scholar
  59. 59.
    Lowenstein CJ, Morrell CN, Yamakuchi M. Regulation of Weibel-Palade body exocytosis. Trends Cardiovasc Med. 2005;15:302–8.PubMedGoogle Scholar
  60. 60.
    Celi A, Pellegrini G, Lorenzet R, De Blasi A, Ready N, Furie BC, et al. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci USA. 1994;91:8767–71.PubMedGoogle Scholar
  61. 61.
    Weyrich AS, McIntyre TM, McEver RP, Prescott SM, Zimmerman GA. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation. J Clin Investig. 1995;95:2297–303.PubMedGoogle Scholar
  62. 62.
    Weyrich AS, Elstad MR, McEver RP, McIntyre TM, Moore KL, Morrissey JH, et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Investig. 1996;97:1525–34.PubMedGoogle Scholar
  63. 63.
    Kilgore KS, Schmid E, Shanley TP, Flory CM, Maheswari V, Tramontini NL, et al. Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. Am J Pathol. 1997;150:2019–31.PubMedGoogle Scholar
  64. 64.
    Torzewski J, Oldroyd R, Lachmann P, Fitzsimmons C, Proudfoot D, Bowyer D. Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol. 1996;16:673–7.PubMedGoogle Scholar
  65. 65.
    Lee C-Y, Lotfi-Emran S, Erdinc M, Murata K, Velidedeoglu E, Fox-Talbot K, et al. The involvement of FcR mechanisms in antibody-mediated rejection. Transplantation. 2007;9:33–43.Google Scholar
  66. 66.
    Qian Z, Jakobs FM, Pfaff-Amesse T, Sanfilippo F, Baldwin WM 3rd. Complement contributes to the rejection of complete and class I major histocompatibility complex–incompatible cardiac allografts. J Heart Lung Transpl. 1998;17:470–8.Google Scholar
  67. 67.
    Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b–C9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem. 1989;264:9053–60.PubMedGoogle Scholar
  68. 68.
    Kilgore KS, Shen JP, Miller BF, Ward PA, Warren JS. Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol. 1995;155:1434–41.PubMedGoogle Scholar
  69. 69.
    Selvan RS, Kapadia HB, Platt JL. Complement-induced expression of chemokine genes in endothelium: regulation by IL-1-dependent and -independent mechanisms. J Immunol. 1998;161:4388–95.PubMedGoogle Scholar
  70. 70.
    Hawrylowicz CM, Howells GL, Feldmann M. Platelet-derived interleukin 1 induces human endothelial adhesion molecule expression and cytokine production. J Exp Med. 1991;174:785–90.PubMedGoogle Scholar
  71. 71.
    Soslau G, Morgan DA, Jaffe JS, Brodsky I, Wang Y. Cytokine mRNA expression in human platelets and a megakaryocytic cell line and cytokine modulation of platelet function. Cytokine. 1997;9:405–11.PubMedGoogle Scholar
  72. 72.
    Ey PL, Prowse SJ, Jenkin CR. Complement-fixing IgG1 constitutes a new subclass of mouse IgG. Nature. 1979;281:492–3.PubMedGoogle Scholar
  73. 73.
    Ey PL, Russell-Jones GJ, Jenkin CR. Isotypes of mouse IgG–I. Evidence for ‘non-complement-fixing’ IgG1 antibodies and characterization of their capacity to interfere with IgG2 sensitization of target red blood cells for lysis by complement. Mol Immunol. 1980;17:699–710.PubMedGoogle Scholar
  74. 74.
    Neuberger MS, Rajewsky K. Activation of mouse complement by monoclonal mouse antibodies. Eur J Immunol. 1981;11:1012–6.PubMedGoogle Scholar
  75. 75.
    White KD, Frank MB, Foundling S, Waxman FJ. Effect of immunoglobulin variable region structure on C3b and C4b deposition. Mol Immunol. 1996;33:759–68.PubMedGoogle Scholar
  76. 76.
    Yokoyama I, Waxman F. Differential susceptibility of immune complexes to release from the erythrocyte CR1 receptor by factor I. Mol Immunol. 1994;31:227–40.Google Scholar
  77. 77.
    Bindon CI, Hale G, Waldmann H. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. Eur J Immunol. 1988;18:1507–14.PubMedGoogle Scholar
  78. 78.
    Dommett RM, Klein N, Turner MW. Mannose-binding lectin in innate immunity: past, present and future. Tissue Antigens. 2006;68:193–209.PubMedGoogle Scholar
  79. 79.
    McMullen ME, Hart ML, Walsh MC, Buras J, Takahashi K, Stahl GL. Mannose-binding lectin binds IgM to activate the lectin complement pathway in vitro and in vivo. Immunobiology. 2006;211:759–66.PubMedGoogle Scholar
  80. 80.
    Chan RK, Ibrahim SI, Takahashi K, Kwon E, McCormack M, Ezekowitz A, et al. The differing roles of the classical and mannose-binding lectin complement pathways in the events following skeletal muscle ischemia-reperfusion. J Immunol. 2006;177:8080–5.PubMedGoogle Scholar
  81. 81.
    Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med. 1995;1:237–43.PubMedGoogle Scholar
  82. 82.
    Berger SP, Roos A, Mallat MJ, Fujita T, de Fijter JW, Daha MR. Association between mannose-binding lectin levels and graft survival in kidney transplantation. Am J Transpl. 2005;5:1361–6.Google Scholar
  83. 83.
    Berger SP, Roos A, Mallat MJ, Schaapherder AF, Doxiadis II, van Kooten C, et al. Low pretransplantation mannose-binding lectin levels predict superior patient and graft survival after simultaneous pancreas-kidney transplantation. J Am Soc Nephrol. 2007;18:2416–22.PubMedGoogle Scholar
  84. 84.
    Imai N, Nishi S, Alchi B, Ueno M, Fukase S, Arakawa M, et al. Immunohistochemical evidence of activated lectin pathway in kidney allografts with peritubular capillary C4d deposition. Nephrol Dial Transpl. 2006;21:2589–95.Google Scholar
  85. 85.
    Sund S, Hovig T, Reisaeter AV, Scott H, Bentdal O, Mollnes TE. Complement activation in early protocol kidney graft biopsies after living-donor transplantation. Transplantation. 2003;75:1204–13.PubMedGoogle Scholar
  86. 86.
    Erdinc M, Mcgregor A, Lucas DP, Leffell MS, Montgomery RA, Zachary AA, et al. IVIg inhibits C1q- and mannose binding lectin (MBL)-dependent deposition of C4d by human alloantibodies. Am J Transpl. 2008;8(s2):568.Google Scholar
  87. 87.
    Fiane AE, Ueland T, Simonsen S, Scott H, Endresen K, Gullestad L, et al. Low mannose-binding lectin and increased complement activation correlate to allograft vasculopathy, ischaemia, and rejection after human heart transplantation. Eur Heart J. 2005;26:1660–5.PubMedGoogle Scholar
  88. 88.
    Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25:21–50.PubMedGoogle Scholar
  89. 89.
    Garred P, Madsen HO, Marquart H, Hansen TM, Sorensen SF, Petersen J, et al. Two edged role of mannose binding lectin in rheumatoid arthritis: a cross sectional study. J Rheumatol. 2000;27:26–34.PubMedGoogle Scholar
  90. 90.
    Rademacher TW, Williams P, Dwek RA. Agalactosyl glycoforms of IgG autoantibodies are pathogenic. Proc Natl Acad Sci USA. 1994;91:6123–7.PubMedGoogle Scholar
  91. 91.
    Bond A, Alavi A, Axford JS, Bourke BE, Bruckner FE, Kerr MA, et al. A detailed lectin analysis of IgG glycosylation, demonstrating disease specific changes in terminal galactose and N-acetylglucosamine. J Autoimmun. 1997;10:77–85.PubMedGoogle Scholar
  92. 92.
    Rook GA, Steele J, Brealey R, Whyte A, Isenberg D, Sumar N, et al. Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. J Autoimmun. 1991;4:779–94.PubMedGoogle Scholar
  93. 93.
    Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature. 1985;316:452–7.PubMedGoogle Scholar
  94. 94.
    Collins C, Tsui FW, Shulman MJ. Differential activation of human and guinea pig complement by pentameric and hexameric IgM. Eur J Immunol. 2002;32:1802–10.PubMedGoogle Scholar
  95. 95.
    Arnold JN, Wormald MR, Suter DM, Radcliffe CM, Harvey DJ, Dwek RA, et al. Human serum IgM glycosylation: identification of glycoforms that can bind to mannan-binding lectin. J Biol Chem. 2005;280:29080–7.PubMedGoogle Scholar
  96. 96.
    Walsh MC, Bourcier T, Takahashi K, Shi L, Busche MN, Rother RP, et al. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol. 2005;175:541–6.PubMedGoogle Scholar
  97. 97.
    Scornik JC, Clapp W, Patton PR, Van der Werf WJ, Hemming AW, Reed AI, et al. Outcome of kidney transplants in patients known to be flow cytometry crossmatch positive. Transplantation. 2001;71:1098–102.PubMedGoogle Scholar
  98. 98.
    Arnold ML, Zacher T, Dechant M, Kalden JR, Doxiadis II, Spriewald BM. Detection and specification of noncomplement binding anti-HLA alloantibodies. Hum Immunol. 2004;65:1288–96.PubMedGoogle Scholar
  99. 99.
    Kushihata F, Watanabe J, Mulder A, Claas F, Scornik JC. Human leukocyte antigen antibodies and human complement activation: role of IgG subclass, specificity, and cytotoxic potential. Transplantation. 2004;78:995–1001.PubMedGoogle Scholar
  100. 100.
    Karuppan SS, Ohlman S, Moller E. The occurrence of cytotoxic and non-complement-fixing antibodies in the crossmatch serum of patients with early acute rejection episodes. Transplantation. 1992;54:839–44.PubMedGoogle Scholar
  101. 101.
    Qian Z, Lee C, Murata K, Liu J, Fox-Talbot K, Wasowska B, et al. Antibody and complement mediated injury in transplants following sensitization by allogeneic blood transfusion. Transplantation. 2006;2006:857–64.Google Scholar
  102. 102.
    Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med. 1994;179:985–92.PubMedGoogle Scholar
  103. 103.
    Kilgore KS, Flory CM, Miller BF, Evans VM, Warren JS. The membrane attack complex of complement induces interleukin-8 and monocyte chemoattractant protein-1 secretion from human umbilical vein endothelial cells. Am J Pathol. 1996;149:953–61.PubMedGoogle Scholar
  104. 104.
    Rus HG, Niculescu FI, Shin M. Role of the C5b-9 complement complex in cell cycle and apoptosis. Immunol Rev. 2001;180:49–55.PubMedGoogle Scholar
  105. 105.
    DiScipio RG, Daffern PJ, Jagels MA, Broide DH, Sriramarao P. A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo. J Immunol. 1999;162:1127–36.PubMedGoogle Scholar
  106. 106.
    Nataf S, Davoust N, Ames RS, Barnum SR. Human T cells express the C5a receptor and are chemoattracted to C5a. J Immunol. 1999;162:4018–23.PubMedGoogle Scholar
  107. 107.
    Schraufstatter IU, Trieu K, Sikora L, Sriramarao P, DiScipio R. Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J Immunol. 2002;169:2102–10.PubMedGoogle Scholar
  108. 108.
    Laudes IJ, Chu JC, Huber-Lang M, Guo RF, Riedemann NC, Sarma JV, et al. Expression and function of C5a receptor in mouse microvascular endothelial cells. J Immunol. 2002;169:5962–70.PubMedGoogle Scholar
  109. 109.
    Bian H, Reed EF. Alloantibody-mediated class I signal transduction in endothelial cells and smooth muscle cells: enhancement by IFN-gamma and TNF-alpha. J Immunol. 1999;163:1010–8.PubMedGoogle Scholar
  110. 110.
    Reznik SI, Jaramillo A, Zhang L, Patterson GA, Cooper JD, Mohanakumar T. Anti-HLA antibody binding to hla class I molecules induces proliferation of airway epithelial cells: a potential mechanism for bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg. 2000;119:39–45.PubMedGoogle Scholar
  111. 111.
    Millan MT, Geczy C, Stuhlmeier KM, Goodman DJ, Ferran C, Bach FH. Human monocytes activate porcine endothelial cells, resulting in increased E-selectin, interleukin-8, monocyte chemotactic protein-1, and plasminogen activator inhibitor-type-1 expression. Transplantation. 1997;63:421–9.PubMedGoogle Scholar
  112. 112.
    Vos IH, Briscoe DM. Endothelial injury: cause and effect of alloimmune inflammation. Transpl Infect Dis. 2002;4:152–9.PubMedGoogle Scholar
  113. 113.
    Pidwell DJ, Heller MJ, Gabler D, Orosz CG. In vitro stimulation of human endothelial cells by sera from a subpopulation of high-percentage panel-reactive antibody patients. Transplantation. 1995;60:563–9.PubMedGoogle Scholar
  114. 114.
    Fredrich R, Toyoda M, Czer LS, Galfayan K, Galera O, Trento A, et al. The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation. Transplantation. 1999;67:385–91.PubMedGoogle Scholar
  115. 115.
    Harris PE, Bian H, Reed EF. Induction of high affinity fibroblast growth factor receptor expression and proliferation in human endothelial cells by anti-HLA antibodies: a possible mechanism for transplant atherosclerosis. J Immunol. 1997;159:5697–704.PubMedGoogle Scholar
  116. 116.
    Narayanan K, Jendrisak MD, Phelan DL, Mohanakumar T. HLA class I antibody mediated accommodation of endothelial cells via the activation of PI3K/cAMP dependent PKA pathway. Transpl Immunol. 2006;15:187–97.PubMedGoogle Scholar
  117. 117.
    Narayanan K, Naziruddin B, Phelan D, Mohanakumar T. Mechanism for in vitro “accommodation” of human aortic endothelial cells by alloantibodies specific for HLA molecules: down regulation of adhesion molecules and over expression of protective genes. Hum Immunol. 2002;63(10 Suppl):S19.Google Scholar
  118. 118.
    Soares MP, Lin Y, Anrather J, Csizmadia E, Takigami K, Sato K, et al. Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat Med. 1998;4:1073–7.PubMedGoogle Scholar
  119. 119.
    Soares MP, Seldon MP, Gregoire IP, Vassilevskaia T, Berberat PO, Yu J, et al. Heme oxygenase-1 modulates the expression of adhesion molecules associated with endothelial cell activation. J Immunol. 2004;172:3553–63.PubMedGoogle Scholar
  120. 120.
    Abdullah N, Greenman J, Pimendiou A, Topping KP, Monson JR. The role of monocytes and natural killer cells in mediating antibody-dependent lysis of colorectal tumor cells. Cancer Immunol Immunother. 1999;48:517–24.PubMedGoogle Scholar
  121. 121.
    Macdermott RP, Nash GS, Merkle NS, Weinrieb IJ, Bertovich MJ, Formeister JF. Further evidence that antibody-dependent and spontaneous cell-mediated cytotoxicity are mediated by different processes or cell types. Immunology. 1980;41:439–47.PubMedGoogle Scholar
  122. 122.
    Miltenburg AMM, Meijer-Paape ME, Weening JJ, Daha MR, van Es LA, van der Woude FJ. Induction of antibody-dependent cellular cytotoxicity against endothelial cells by renal transplantation. Transplantation. 1989;48:681.PubMedGoogle Scholar
  123. 123.
    van de Winkel JG, Capel PJ. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today. 1993;14:215–21.PubMedGoogle Scholar
  124. 124.
    Schmidt RE, Gessner JE. Fc receptors and their interaction with complement in autoimmunity. Immunol Lett. 2005;100:56–67.PubMedGoogle Scholar
  125. 125.
    Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001;19:275–90.PubMedGoogle Scholar
  126. 126.
    Daeron M. Fc receptor biology. Annu Rev Immunol. 1997;15:203–34.PubMedGoogle Scholar
  127. 127.
    Bolland S, Ravetch JV. Inhibitory pathways triggered by ITIM-containing receptors. Adv Immunol. 1999;72:149–77.PubMedGoogle Scholar
  128. 128.
    Nimmerjahn F, Ravetch JV. Fc-receptors as regulators of immunity. Adv Immunol. 2007;96:179–204.PubMedGoogle Scholar
  129. 129.
    Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity. 2005;23:41–51.PubMedGoogle Scholar
  130. 130.
    Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34–47.Google Scholar
  131. 131.
    Boot JHA, Geerts MEJ, Aarden LA. Functional polymorphisms of Fc receptor in human monocyte-mediated cytotoxicity towards erythrocytes induced by murine isotype switch variants. J Immunol. 1989;142:1217.PubMedGoogle Scholar
  132. 132.
    Ravetch JV, Kinet JP. Fc receptors. Annu Rev Immunol. 1991;9:457–92.PubMedGoogle Scholar
  133. 133.
    Dijstelbloem HM, van de Winkel JG, Kallenberg CG. Inflammation in immunity: receptors for IgG revisited. Trends Immunol. 2001;22:510–6.PubMedGoogle Scholar
  134. 134.
    Kirby JA, Givan AL, Shenton BK, Talbot D, Forsythe JL, Lennard TW, et al. Renal allograft rejection. Possible involvement of antibody-dependent cell-mediated cytotoxicity. Transplantation. 1990;50:225–9.PubMedGoogle Scholar
  135. 135.
    Marsh CB, Wewers MD, Tan LC, Rovin BH. Fc(gamma) receptor cross-linking induces peripheral blood mononuclear cell monocyte chemoattractant protein-1 expression: role of lymphocyte Fc(gamma)RIII. J Immunol. 1997;158:1078–84.PubMedGoogle Scholar
  136. 136.
    Marsh CB, Gadek JE, Kindt GC, Moore SA, Wewers MD. Monocyte Fc gamma receptor cross-linking induces IL-8 production. J Immunol. 1995;155:3161–7.PubMedGoogle Scholar
  137. 137.
    Sekine Y, Yasufuku K, Heidler KM, Cummings OW, Van Rooijen N, Fujisawa T, et al. Monocyte chemoattractant protein-1 and RANTES are chemotactic for graft infiltrating lymphocytes during acute lung allograft rejection. Am J Respir Cell Mol Biol. 2000;23:719–26.PubMedGoogle Scholar
  138. 138.
    Nadeau KC, Azuma H, Tilney NL. Sequential cytokine expression in renal allografts in rats immunosuppressed with maintenance cyclosporine or mycophenolate mofetil. Transplantation. 1996;62:1363–6.PubMedGoogle Scholar
  139. 139.
    Russell ME, Wallace AF, Hancock WW, Sayegh MH, Adams DH, Sibinga NE, et al. Upregulation of cytokines associated with macrophage activation in the Lewis-to-F344 rat transplantation model of chronic cardiac rejection. Transplantation. 1995;59:572–8.PubMedGoogle Scholar
  140. 140.
    Lones MA, Czer LS, Trento A, Harasty D, Miller JM, Fishbein MC. Clinical-pathologic features of humoral rejection in cardiac allografts: a study in 81 consecutive patients. J Heart Lung Transpl. 1995;14:151–62.Google Scholar
  141. 141.
    Magil AB, Tinckam K. Monocytes and peritubular capillary C4d deposition in acute renal allograft rejection. Kidney Int. 2003;63:1888–93.PubMedGoogle Scholar
  142. 142.
    Erwig LP, Kluth DC, Walsh GM, Rees AJ. Initial cytokine exposure determines function of macrophages and renders them unresponsive to other cytokines. J Immunol. 1998;161:1983–8.PubMedGoogle Scholar
  143. 143.
    Chouchakova N, Skokowa J, Baumann U, Tschernig T, Philippens KM, Nieswandt B, et al. Fc gamma RIII-mediated production of TNF-alpha induces immune complex alveolitis independently of CXC chemokine generation. J Immunol. 2001;166:5193–200.PubMedGoogle Scholar
  144. 144.
    Latour S, Bonnerot C, Fridman WH, Daeron M. Induction of tumor necrosis factor-alpha production by mast cells via Fc gamma R. Role of the Fc gamma RIII gamma subunit. J Immunol. 1992;149:2155–62.PubMedGoogle Scholar
  145. 145.
    Wang ZQ, Bapat AS, Rayanade RJ, Dagtas AS, Hoffmann MK. Interleukin-10 induces macrophage apoptosis and expression of CD16 (FcgammaRIII) whose engagement blocks the cell death programme and facilitates differentiation. Immunology. 2001;102:331–7.PubMedGoogle Scholar
  146. 146.
    Coxon A, Cullere X, Knight S, Sethi S, Wakelin MW, Stavrakis G, et al. Fc gamma RIII mediates neutrophil recruitment to immune complexes. A mechanism for neutrophil accumulation in immune-mediated inflammation. Immunity. 2001;14:693–704.PubMedGoogle Scholar
  147. 147.
    Abrahams VM, Cambridge G, Lydyard PM, Edwards JC. Induction of tumor necrosis factor alpha production by adhered human monocytes: a key role for Fcgamma receptor type IIIa in rheumatoid arthritis. Arthritis Rheum. 2000;43:608–16.PubMedGoogle Scholar
  148. 148.
    Shushakova N, Skokowa J, Schulman J, Baumann U, Zwirner J, Schmidt RE, et al. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J Clin Investig. 2002;110:1823–30.PubMedGoogle Scholar
  149. 149.
    Kumar V, Ali SR, Konrad S, Zwirner J, Verbeek JS, Schmidt RE, et al. Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. J Clin Investig. 2006;116:512–20.PubMedGoogle Scholar
  150. 150.
    Bajtay Z, Jozsi M, Banki Z, Thiel S, Thielens N, Erdei A. Mannan-binding lectin and C1q bind to distinct structures and exert differential effects on macrophages. Eur J Immunol. 2000;30:1706–13.PubMedGoogle Scholar
  151. 151.
    Mcgregor A, Fox-Talbot K, Velidedeoglu E, Baldwin WMI, Wasowska BA. The absence of FcgRIII results in increased pro-inflammatory response in FcgRIII KO cardiac allograft recipients. Am J Transpl. 2009;9(s2):481.Google Scholar
  152. 152.
    Park-Min KH, Serbina NV, Yang W, Ma X, Krystal G, Neel BG, et al. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity. 2007;26:67–78.PubMedGoogle Scholar
  153. 153.
    Clynes R. IVIG therapy: interfering with interferon-gamma. Immunity. 2007;26:4–6.Google Scholar
  154. 154.
    Clynes R. Protective mechanisms of IVIG. Curr Opin Immunol. 2007;19:646–51.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of PathologyThe Johns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations